Nodal and leukemic small B-cell neoplasms

Modern Pathology

Volumn 26, Issue , 2013, Pages 15-28

  Cook, James R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

CLL SLL; Follicular lymphoma; Lymphoplasmacytic lymphoma; Mantle cell lymphoma; Marginal zone lymphoma; Small B cell neoplasms

Indexed keywords

CYCLIN D1;

B CELL LYMPHOMA; CANCER DIAGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; DISEASE SEVERITY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MONOCLONAL B CELL LYMPHOCYTOSIS; NODAL MARGINAL ZONE LYMPHOMA; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SMALL B CELL LYMPHOMA; SMALL LYMPHOCYTIC LYMPHOMA; WALDENSTROEM MACROGLOBULINEMIA;

B-LYMPHOCYTES; DIAGNOSIS, DIFFERENTIAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR;

EID: 84871864757     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.180     Document Type: Article

References (95)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2008.
2. Carbone A, Santoro A. How I treat: diagnosing and managing ‘in situ’ lymphoma. Blood 2011;117: 3954-3960.
3. Harris NL, Swerdlow SH, Jaffe ES, et al. Follicular lymphoma, In: Swerdlow SH, Campo E, Harris NL, et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. IARC Press: Lyon; 2008, pp 220-226.
4. Piccaluga PP, Sapienza MR, Agostinelli C, et al. Biology and treatment of follicular lymphoma. Expert Rev Hematol 2009;2:533-547.
5. The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997;89:3909-3918.
6. Wahlin BE, Yri OE, Kimby E, et al. Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol 2012;156:225-233.
7. Horn H, Schmelter C, Leich E, et al. Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica 2011;96:1327-1334.
8. Chen CC, Raikow RB, Sonmez-Alpan E, et al. Classification of small B-cell lymphoid neoplasms using a paraffin section immunohistochemical panel. Appl Immunohistochem Mol Morphol 2000;8:1-11.
9. Dogan A, Bagdi E, Munson P, et al. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. The Am J Surg Pathol 2000;24:846-852.
10. Dogan A, Du MQ, Aiello A, et al. Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone. Blood 1998;91:4708-4714.
11. Cook JR, Craig FE, Swerdlow SH. bcl-2 expression by multicolor flow cytometric analysis assists in the diagnosis of follicular lymphoma in lymph node and bone marrow. Am J Clin Pathol 2003;119:145-151.
12. Guo Y, Karube K, Kawano R, et al. Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances. Leukemia 2005;19:1058-1063.
13. Ott G, Katzenberger T, Lohr A, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002;99:3806-3812.
14. Goteri G, Lucarini G, Zizzi A, et al. Comparison of germinal center markers CD10, BCL6 and human germinal center-associated lymphoma (HGAL) in follicular lymphomas. Diagn Pathol 2011;6:97.
15. Montes-Moreno S, Roncador G, Maestre L, et al. Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. Blood 2008; 111:351-358.
16. Natkunam Y, Lossos IS, Taidi B, et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood 2005;105:3979-3986.
17. Younes SF, Beck AH, Lossos IS, et al. Immunoarchitectural patterns in follicular lymphoma: efficacy of HGAL and LMO2 in the detection of the interfollicular and diffuse components. Am J Surg Pathol 2010; 34:1266-1276.
18. Cook JR. Paraffin section interphase fluorescence in situ hybridization in the diagnosis and classification of non-hodgkin lymphomas. Diagn Mol Pathol 2004; 13:197-206.
19. Lu G, Kong Y, Yue C. Genetic and immunophenotypic profile of IGH@ rearrangement detected by fluorescence in situ hybridization in 149 cases of B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 2010;196:56-63.
20. Baseggio L, Geay MO, Gazzo S, et al. In non-follicular lymphoproliferative disorders, IGH/BCL2-fusion is not restricted to chronic lymphocytic leukaemia. Br J Haematol 2012;158:489-498.
21. Belaud-Rotureau M-A, Parrens M, Carrere N, et al. Interphase fluorescence in situ hybridization is more sensitive than BIOMED-2 polymerase chain reaction protocol in detecting IGH-BCL2 rearrangement in both fixed and frozen lymph node with follicular lymphoma. Human Pathol 2007;38:365-372.
22. Espinet B, Bellosillo B, Melero C, et al. FISH is better than BIOMED-2 PCR to detect IgH/BCL2 translocation in follicular lymphoma at diagnosis using paraffinembedded tissue sections. Leukemia Res 2008;32: 737-742.
23. Weinberg OK, Ai WZ, Mariappan MR, et al. ‘Minor’ BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases. J Mol Diagn 2007;9:530-537.
24. Masir N, Campbell LJ, Goff LK, et al. BCL2 protein expression in follicular lymphomas with t(14;18) chromosomal translocations. Br J Haematol 2009; 144:716-725.
25. Masir N, Campbell LJ, Jones M, et al. Pseudonegative BCL2 protein expression in a t(14;18) translocation positive lymphoma cell line: a need for an alternative BCL2 antibody. Pathology 2010;42:212-216.
26. Guo Y, Karube K, Kawano R, et al. Bcl2-negative follicular lymphomas frequently have Bcl6 translocation and/or Bcl6 or p53 expression. Pathol Int 2007;57:148-152.
27. Oschlies I, Salaverria I, Mahn F, et al. Pediatric follicular lymphoma—a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin’s Lymphoma—Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica 2010; 95:253-259.
28. Swerdlow SH. Pediatric follicular lymphomas, marginal zone lymphomas, and marginal zone hyperplasia. Am J Clin Pathol 2004;122(Suppl):S98-S109.
29. Kussick SJ, Kalnoski M, Braziel RM, et al. Prominent clonal B-cell populations identified by flow cytometry in histologically reactive lymphoid proliferations. Am J Clin Pathol 2004;121:464-472.
30. Salaverria I, Philipp C, Oschlies I, et al. Translocations activating IRF4 identify a subtype of germinal centerderived B-cell lymphoma affecting predominantly children and young adults. Blood 2011;118:139-147.
31. Schmitt C, Balogh B, Grundt A, et al. The bcl-2/IgH rearrangement in a population of 204 healthy individuals: occurrence, age and gender distribution, breakpoints, and detection method validity. Leuk Res 2006;30:745-750.
32. Summers KE, Goff LK, Wilson AG, et al. Frequency of the Bcl-2/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma. J Clin Oncol 2001;19: 420-424.
33. Cong P, Raffeld M, Teruya-Feldstein J, et al. In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. Blood 2002;99:3376-3382.
34. Jegalian AG, Eberle FC, Pack SD, et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood 2011;118:2976-2984.
35. Carbone A, Gloghini A, Santoro A. In situ follicular lymphoma: pathologic characteristics and diagnostic features. Hematol Oncol 2012;30:1-7.
36. Henopp T, Quintanilla-Martinez L, Fend F, et al. Prevalence of follicular lymphoma in situ in consecutively analysed reactive lymph nodes. Histopathology 2011;59:139-142.
37. Muller-Hermelink HK, Montserrat E, Catovsky D, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, In: Swerdlow SH, Campo E, Harris NL, et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon; 2008, pp 180-184.
38. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
39. Dighiero G. Unsolved issues in CLL biology and management. Leukemia 2003;17:2385-2391.
40. Gine E, Martinez A, Villamor N, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (‘accelerated’ chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 2010;95:1526-1533.
41. Frater JL, McCarron KF, Hammel JP, et al. Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypically. Am J Clin Pathol 2001;116:655-664.
42. Ho AK, Hill S, Preobrazhensky SN, et al. Small B-cell neoplasms with typical mantle cell lymphoma immunophenotypes often include chronic lymphocytic leukemias. Am J Clin Pathol 2009;131:27-32.
43. Moreau EJ, Matutes E, A’Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997;108:378-382.
44. Tandon B, Peterson L, Gao J, et al. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas. Mod Pathol 2011;24:1433-1443.
45. Chen YH, Gao J, Fan G, et al. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod Pathol 2010;23:105-112.
46. Ek S, Dictor M, Jerkeman M, et al. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 2008;111:800-805.
47. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009;94:1555-1562.
48. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. New Engl J Med 2000;343:1910-1916.
49. Zenz T, Mertens D, Dohner H, et al. Importance of genetics in chronic lymphocytic leukemia. Blood Rev 2011;25:131-137.
50. Flanagan MB, Sathanoori M, Surti U, et al. Cytogenetic abnormalities detected by fluorescence in situ hybridization on paraffin-embedded chronic lymphocytic leukemia/small lymphocytic lymphoma lymphoid tissue biopsy specimens. Am J Clin Pathol 2008;130:620-627.
51. Marti GE, Rawstron AC, Ghia P, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 2005;130:325-332.
52. Shanafelt TD, Ghia P, Lanasa MC, et al. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia 2010;24:512-520.
53. Shanafelt TD, Kay NE, Jenkins G, et al. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood 2009;113:4188-4196.
54. Molica S, Mauro FR, Giannarelli D, et al. Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group. Haematologica 2011;96:277-283.
55. Ghia P. Another piece of the puzzle: is there a ‘nodal’ monoclonal B-cell lymphocytosis? Haematologica 2011;96:1089-1091.
56. Gibson SE, Swerdlow SH, Ferry JA, et al. Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis. Haematologica 2011;96:1144-1152.
57. Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019-5032.
58. Swerdlow SH, Campo E, Seto M, et al. Mantle cell lymphoma, In: Swerdlow SH, Campo E, Harris NL, et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon; 2008, pp 229-232.
59. Klapper W. Histopathology of mantle cell lymphoma. Semin Hematol 2011;48:148-154.
60. Kurtin PJ. Indolent lymphomas of mature B lymphocytes. Hematol Oncol Clin North Am 2009;23:769-790.
61. Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997;89:2067-2078.
62. Bernard M, Gressin R, Lefrere F, et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia 2001;15:1785-1791.
63. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005;131:29-38.
64. Kimura Y, Sato K, Arakawa F, et al. Mantle cell lymphoma shows three morphological evolutions of classical, intermediate, and aggressive forms, which occur in parallel with increased labeling index of cyclin D1 and Ki-67. Cancer Sci 2010;101:806-814.
65. Liu Z, Dong HY, Gorczyca W, et al. CD5-mantle cell lymphoma. Am J Clin Pathol 2002;118:216-224.
66. Xu W, Li J-Y. SOX11 expression in mantle cell lymphoma. Leuk Lymphoma 2010;51:1962-1967.
67. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7:750-762.
68. Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011; 117:26-38.
69. Williams ME, Connors JM, Dreyling MH, et al. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leuk Lymphoma 2011;52:24-33.
70. Komatsu H, Iida S, Yamamoto K, et al. A variant chromosome translocation at 11q13 identifying PRAD1/cyclin D1 as the BCL-1 gene. Blood 1994;84:1226-1231.
71. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005;106:4315-4321.
72. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185-197.
73. Hunt KE, Reichard KK, Wilson CS. Mantle cell lymphoma lacking the t(11;14) translocation: a case report and brief review of the literature. J Clin Pathol 2008;61:869-870.
74. Wlodarska I, Dierickx D, Vanhentenrijk V, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 2008;111:5683-5690.
75. Carvajal-Cuenca A, Salaverria I, Royo C, et al. Clinicopathologic characterization of cyclin D1-negative mantle cell lymphoma. Lab Invest 2012;92:326a-327a.
76. Fernandez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70: 1408-1418.
77. Ondrejka SL, Lai R, Smith SD, et al. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 2011;96: 1121-1127.
78. Lecluse Y, Lebailly P, Roulland S, et al. t(11;14)-positive clones can persist over a long period of time in the peripheral blood of healthy individuals. Leukemia 2009;23:1190-1193.
79. Carvajal-Cuenca A, Sua LF, Silva NM, et al. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica 2011;97:270-278.
80. Arcaini L, Lucioni M, Boveri E, et al. Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease. Eur J Haematol 2009;83:165-174.
81. Campo E, Pileri S, Jaffe ES, et al. Nodal marginal zone lymphoma, In: Swerdlow SH, Campo E, Harris NL, et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. IARC Press: Lyon; 2008, pp 218-219.
82. Cousar JB, McGinn DL, Glick AD, et al. Report of an unusual lymphoma arising from parafollicular B-lymphocytes (PBLs) or so-called ‘monocytoid’ lymphocytes. Am J Clin Pathol 1987;87:121-128.
83. Sheibani K, Sohn CC, Burke JS, et al. Monocytoid B-cell lymphoma. A novel B-cell neoplasm. American J Pathol 1986;124:310-318.
84. Molina TJ, Lin P, Swerdlow SH, et al. Marginal zone lymphomas with plasmacytic differentiation and related disorders. Am J Clin Pathol 2011;136:211-225.
85. Traverse-Glehen A, Felman P, Callet-Bauchu E, et al. A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology 2006;48:162-173.
86. Taddesse-Heath L, Pittaluga S, Sorbara L, et al. Marginal zone B-cell lymphoma in children and young adults. The Am J Surg Pathol 2003;27:522-531.
87. Attygalle AD, Liu H, Shirali S, et al. Atypical marginal zone hyperplasia of mucosa-associated lymphoid tissue: a reactive condition of childhood showing immunoglobulin lambda light-chain restriction. Blood 2004;104:3343-3348.
88. Andriko JA, Swerdlow SH, Aguilera NI, et al. Is lymphoplasmacytic lymphoma/immunocytoma a distinct entity? A clinicopathologic study of 20 cases. Am J Surg Pathol 2001;25:742-751.
89. Lin P, Medeiros LJ. Lymphoplasmacytic lymphoma/ waldenstrom macroglobulinemia: an evolving concept. Adv Anat Pathol 2005;12:246-255.
90. Swerdlow SH, Berger F, Pileri SA, et al. Lymphoplasmacytic Lymphoma, In: Swerdlow SH, Campo E, Harris NL, et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon; 2008, pp 194-195.
91. Cook JR, Aguilera NI, Reshmi S, et al. Deletion 6q is not a characteristic marker of nodal lymphoplasmacytic lymphoma. Cancer Genet Cytogenet 2005;162: 85-88.
92. Lin P, Molina TJ, Cook JR, et al. Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation. Am J Clin Pathol 2011;136:195-210.
93. Cook JR, Aguilera NI, Reshmi-Skarja S, et al. Lack of PAX5 rearrangements in lymphoplasmacytic lymphomas: reassessing the reported association with t(9;14). Hum Pathol 2004;35:447-454.
94. Treon SP, Xu L, Zhou YS, et al. Whole genome sequencing reveals a widely expressed mutation (MYD88 L265P) with oncogenic activity in Waldenstrom’s macroglobulinemia. Blood 2011;118:140.
95. Xu L, Sohani AR, Arcaini L, et al. A somatic variant in MYD88 (L265P) revealed by whole genome sequencing differentiates lymphoplasmacytic lymphoma from marginal zone lymphomas. Blood 2011;118:120.